Insmed (NASDAQ:INSM) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Insmed (NASDAQ:INSM) in a research note released on Monday, Marketbeat reports. The firm issued an overweight rating and a $171.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on INSM. Guggenheim lifted their price target on Insmed from $125.00 to $172.00 and gave the stock a “buy” rating in a report on Monday, September 8th. Jefferies Financial Group boosted their target price on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. Royal Bank Of Canada boosted their target price on Insmed from $108.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Evercore ISI restated an “outperform” rating and issued a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. Finally, TD Cowen boosted their target price on Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus price target of $152.88.

Insmed Stock Performance

Shares of Insmed stock opened at $167.91 on Monday. The business’s fifty day simple moving average is $144.48 and its 200 day simple moving average is $105.96. The firm has a market capitalization of $35.49 billion, a P/E ratio of -29.41 and a beta of 1.03. Insmed has a 12 month low of $60.40 and a 12 month high of $168.22. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business’s revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Roger Adsett sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares in the company, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 152,657 shares of company stock worth $21,442,198 in the last 90 days. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently added to or reduced their stakes in INSM. Norges Bank bought a new position in Insmed in the 2nd quarter worth about $194,728,000. Adage Capital Partners GP L.L.C. increased its stake in Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after acquiring an additional 1,799,382 shares during the last quarter. Orbis Allan Gray Ltd bought a new position in Insmed in the 2nd quarter worth about $153,389,000. Nuveen LLC bought a new position in Insmed in the 1st quarter worth about $88,351,000. Finally, Qube Research & Technologies Ltd bought a new position in Insmed in the 2nd quarter worth about $108,898,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.